Los Angeles,
06:00 AM

Cancer Physicians, Investigators Available for Interviews Throughout ASCO GU

Leading Experts From Cedars-Sinai Cancer Can Discuss the Latest Breakthroughs in the Diagnostics and Treatment of Genitourinary Malignancies

Physician-scientists from Cedars-Sinai Cancer are available to discuss the latest breakthroughs in the diagnostics and treatment of genitourinary cancers throughout the 2023 ASCO Genitourinary Cancers Symposium, taking place in San Francisco Feb. 16-18.

Experts and topics include:

  • Rapid abstract session sharing results from the randomized, double-blinded Phase II study of ketoconazole, hydrocortisone, and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients with high-risk non-metastatic castration-resistant prostate cancer. 
    Expert: Edwin Posadas, MD, medical director of the Urologic Oncology Program at Cedars-Sinai Cancer 
  • Patient-level data meta-analysis of a multi-modal artificial intelligence prognostic biomarker in high-risk prostate cancer: Results from six NRG/RTOG Phase III randomized trials.
    Expert: Howard Sandler, MD, chair of the Department of Radiation Oncology at Cedars-Sinai Cancer
  • Urothelial carcinoma, also known as transitional cell carcinoma, the most common type of bladder cancer.
    Expert: Leslie Ballas, MD, radiation oncologist at Cedars-Sinai Cancer
  • Various population health-related topics in prostate and bladder cancer, including racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-sensitive prostate cancer.
    Expert: Stephen Freedland, MD, director of the Center for Integrated Research in Cancer and Lifestyle at Cedars-Sinai Cancer

Interviews can be arranged to take place in person at Cedars-Sinai, or by using most virtual meeting formats, including Zoom, FaceTime and Skype.

CONTACT: Cara Martinez can help schedule your interview: 310-562-7821 or Cara.Martinez@cshs.org.